CYB5R1 is a potential biomarker that correlates with stemness and drug resistance in gastric cancer

• Published in: Translational oncology Vol. 39; p. 101766
• Main Authors: Zhang, Qin, Ma, Yufan, Yan, Yongfeng, Zhang, Lu, Zhang, Yajun
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.01.2024; Neoplasia Press; Elsevier
• Subjects: CYB5R1; Drug resistance; Gastric cancer; NFS1; Original Research; Stemness; CYB5R1; Stemness; NFS1; Drug resistance; Gastric cancer
• ISSN: 1936-5233; 1936-5233
• DOI: 10.1016/j.tranon.2023.101766

•CYB5R1 was identified and shown to be highly expressed with poor prognosis in gastric cancer.•CYB5R1 participated in drug resistance and tumorigenesis.•Protein-protein interaction indicated CYB5R1 and NFS1 expression levels are positively correlated. Drug resistance is a major obstacle in the treatment of gastric cancers (GC). In recent years, the prognostic value of the mRNA expression-based stemness score (mRNAss) across cancers has been reported. We intended to search for the key genes associated with Cancer stem cells (CSCs) and drug resistance. All GC samples from The Cancer Genome Atlas (TCGA) were then divided into low- and high-mRNAss groups based on the median value of mRNAss. A weighted correlation network analysis (WCGNA) was used to identify co-expressed genes related to mRNAss groups. Differential gene expression analysis with Limma was performed in the GSE31811. The correlations between CYB5R1 and the immune cells and macrophage infiltration were analyzed by TIMER database. Spheroid formation assay was used to evaluate the stemness of gastric cancer cells, and transwell assay was used to detect the invasion and migration ability of gastric cancer cells. GC patients with high mRNAss values had a worse prognosis than those with low mRNAss values. 584 genes were identified by WGCNA analysis. 668 differentially expressed genes (DEGs) (|logFC|>1) with 303 down-regulated and 365 up-regulated were established in drug-effective patients compared to controls. TCGA-STAD samples were divided into 3 subtypes based on 303 down-regulated genes. CYB5R1 was a potential biomarker that correlated with the response to drugs in GC (AUC=0.83). CYB5R1 participated in drug resistance and tumorigenesis through NFS1 in GC. Our study highlights the clinical importance of CYB5R1 in GC and the CYB5R1-NFS1 signaling-targeted therapy might be a feasible strategy for the treatment of GC.